Correlation of tumor necrosis factor alpha and interleukin 6 with hypertensive renal damage

Renal Failure

Volumn 32, Issue 4, 2010, Pages 475-479

  Yu, Xin ^a   Yang, Zhen ^b   Yu, Meiling ^b  

^a NINGXIA MEDICAL UNIVERSITY   (China)

^b AFFILIATED HOSPITAL OF NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

Essential hypertension; Interleukin 6; Renal damage; Tumor necrosis factor alpha; Urinary albumin excretion rate

Indexed keywords

ALBUMIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; KIDNEY INJURY; MAJOR CLINICAL STUDY; MICROALBUMINURIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RADIOIMMUNOASSAY; SAMPLING; URINARY EXCRETION;

ALBUMINURIA; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; FEMALE; HUMANS; HYPERTENSION; INTERLEUKIN-6; KIDNEY DISEASES; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952146703     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860221003664280     Document Type: Article

References (31)

1. Cymerys M, Chyrek R, Bogdanski P, Lacki J, Pupek-Musialik D. Evaluation of acute phase proteins in hypertensive and obese patients. Pol Merkuriusz Lek. 2003;15:352-355.
2. Bogdanski P, Kujawska-Luczak M, Lacki J, Pupek-Musialik D. Evaluation of selected interleukins, tumor necrosis factor, insulin and leptin in obese patient with hypertension. Pol Merkuriusz Lek. 2003;15:347-351.
3. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005;19:149-154.
4. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension. 2001; 38:399-403.
5. Cottone S, Vadalà A, Vella MC, Mulé G, Contorno A, Cerasola G. Comparison of tumor necrosis factor and endothelin-1 between essential and renal hypertension patients. J Hum Hypertens. 1998;12:351-354.
6. Dzielak DJ. The immune system and hypertension. Hypertension. 1992;19(Suppl. 1):I36-I44.
7. Sardo MA, Mandraffino G, Campo S, et al. Biglycan expression in hypertensive subjects with normal or increased carotid intima-media wall thickness. Clin Chim Acta. 2009; 406(1-2):89-93.
8. Kim KI, Lee JH, Chang HJ, et al. Association between blood pressure variability and inflammatory marker in hypertensive patients. Circ J. 2008;72:293-298.
9. Bivol LM, Berge RK, Iversen BM. Tetradecylthioacetic acid prevents the inflammatory response in two-kidney, one-clip hypertension. Am J Physiol Regul Integr Comp Physiol. 2008; 294:R438-R447.
10. Conrad KP, Benyo DF. Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol. 1997;37:240-249.
11. Marsden PA, Brenner BM. Transcriptional regulation of the endothelin- 1 gene by TNF-a. Am J Physiol. 1992;262: C854-C861.
12. Hajjar KA, Hajjar DP, Silverstein RL, Nachman RL. Tumor necrosis factor-mediated release of platelet-derived growth factor from cultured endothelia cells. J Exp Med. 1987;166: 235-245.
13. Van Hinsbergh VW, Kooistra T, van den Berg EA, Princen HM, Fiers W, Emeis JJ. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and rats in vivo. Blood. 1988;72:1467-1473.
14. Ikeda U, Ikeda M, Oohara T, et al. Interleukin 6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am J Physiol. 1991;260:H1713-H1717.
15. Yoshizumi M, Perrella MA, Burnett JC Jr, Lee ME. Tumor necrosis factor down regulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res. 1993;73:205-209.
16. Naya M, Tsukamoto T, Morita K, et al. Plasma interleukin-6 and tumor necrosis factor-alpha can predict coronary endothelial dysfunction in hypertensive patients. Hypertens Res. 2007;30:541-548.
17. Han Y, Runge MS, Brasier AR. Angiotensin II induces interleukin- 6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor kappa B transcription factors. Circ Res. 1999;84:695-703.
18. Skurk T, van Harmelen V, Hauner H. Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of nuclear factor kappa B. Arterioscler Thromb Vasc Biol. 2004;24:1199-1203.
19. Kranzhöfer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kübler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19:1623-1629.
20. Brasier AR, Li J, Wimbish KA. Tumor necrosis factor activates angiotensinogen gene expression by Rel A transactivator. Hypertension. 1996;27:1009-1017.
21. Takano M, Itoh N, Yayama K, Yamano M, Ohtani R, Okamoto H. Interleukin-6 as a mediator responsible for inflammation-induced increase in plasma angiotensinogen. Biochem Pharmacol. 1993;45:201-206.
22. Buemi M, Marino D, Floccari F, et al. Effect of interleukin-8 and ICAM-1 on calcium-dependent outflow of K+ in erythrocytes from subjects with essential hypertension. Curr Med Res Opin. 2004;20:19-24.
23. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension. 2005;46: 1118-1122.
24. Simmons EM, Himmelfarb J, Sezer MT, et al. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int. 2004;65:1357-1365. (Pubitemid 38406974)
25. Pecoits-Filho R, Bárány P, Lindholm B, Heimbürger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant. 2002;17:1684-1688.
26. Coletta I, Soldo L, Polentarutti N, et al. Selective induction of MCP-1 in human mesangial cells by the IL-6/sIL-6R complex. Exp Nephrol. 2000;8:37-43.
27. Nanami M, Ookawara T, Otaki Y, et al. Tumor necrosis factor alpha induced iron sequestration and oxidative stress in human endothelial cells. Arterioscler Thromb Vasc Biol. 2005;25:2495-2501.
28. Sterzel RB, Schulze-Lohoff E, Marx M. Cytokines and mesangial cells. Kidney Int Suppl. 1993;39:26-31.
29. Ruef C, Budde K, Lacy J, et al. Interleukin 6 is an autocrine growth factor for mesangial cells. Kidney Int. 1990; 38:249-257.
30. Horii Y, Muraguchi A, Iwano M, et al. Involvement of IL-6 in mesangial proliferative glomerulonephritis. J Immunol. 1989; 143:3949-3955.
31. Ritz E, Stefanski A. Diabetic nephropathy in type2 diabetes. Am J Kidney Dis. 1996;27:167-194.